ArticleOpen forum infectious diseases2021
Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients.
Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Association of early ondansetron use with 30-day mortality in patients with acute respiratory distress syndrome: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Article
- The correlation between the use of ondansetron and mortality in sepsis associated encephalopathy patients: a retrospective ICU cohort study.Frontiers in pharmacology · 2025Article
- The therapeutic targets and signaling mechanisms of ondansetron in the treatment of critical illness in the ICU.Frontiers in pharmacology · 2024Article
- The association between ondansetron use and mortality risk of traumatic brain injury patients: a population-based study.Frontiers in pharmacology · 2024Article
- Metformin is associated with reduced COVID-19 severity in patients with prediabetes.Diabetes research and clinical practice · 2022Observational
- Hypothesis-Agnostic Network-Based Analysis of Real-World Data Suggests Ondansetron is Associated with Lower COVID-19 Any Cause Mortality.Drugs - real world outcomes · 2022Article
- Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2.Translational psychiatry · 2022Article
- Association between early ondansetron administration and in-hospital mortality in critically ill patients: analysis of the MIMIC-IV database.Journal of translational medicine · 2022Article
- Early Postoperative Ondansetron Exposure is Associated with Reduced 90-Day Mortality in Patients Undergoing Cardiac Surgery.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) pandemic has led to a surge in clinical trials evaluating investigational and approved drugs. Retrospective analysis of drugs taken by COVID-19 inpatients provides key information on drugs associated with better or worse outcomes.
methodsWe conducted a retrospective cohort study of 10 741 patients testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 days of admission to compare risk of 30-day all-cause mortality in patients receiving ondansetron using multivariate Cox proportional hazard models. All-cause mortality, length of hospital stay, adverse events such as ischemic cerebral infarction, and subsequent positive COVID-19 tests were measured.
resultsAdministration of ≥8 mg of ondansetron within 48 hours of admission was correlated with an adjusted hazard ratio for 30-day all-cause mortality of 0.55 (95% CI, 0.42-0.70;
conclusionsIf confirmed by prospective clinical trials, our results suggest that ondansetron, a safe, widely available drug, could be used to decrease morbidity and mortality in at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.